A new percutaneous approach for the treatment of hydatid cysts of the liver

Örmeci, Necati; Soykan, İrfan; Bektaş, Ahmet; Sarioğlu, Mustafa; Palabiyikoğlu, Murat; Yaşa, M Hadi; Dökmeci, Abdülkadir; Uzunalımoǧlu, Özden

doi:10.1111/j.1572-0241.2001.03886.x

Cited by 34 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As polidocanol has been proposed for use as a sclerosing compound in treatment of diverse hepatic diseases such as intrahepatic cysts (Kaneko et al 2002;Ormeci et al 2001), the present data demonstrating a potential deleterious effect if polidocanol enters the hepatic vascular system have to be taken into account and polidocanol instillation may be performed under great caution.…”

Section: Mean Sd Mean Sdmentioning

confidence: 76%

“…As polidocanol is routinely used for sclerosing varices and other vascular pathologies in the gastrointestinal tract (Morales and Baum 2003;Vlavianos and Westaby 2001) and it has recently been proposed for use in the treatment different hepatic diseases (Kaneko et al 2002;Ormeci et al 2001), the present study addressed its effects when administered to the hepatic vascular system because the liver plays an important role in the metabolism of exogenous substances due to its anatomical position between the gastrointestinal tract and the systemic circulation.…”

Section: Discussionmentioning

confidence: 99%

“…It is known to have a low risk of systemic and local complications (Conrad et al 1995;Feied et al 1994), and therefore it is commonly used for sclerotherapy, which is a relatively safe and worldwide-used therapeutic option for the treatment of various diseases (Sharara and Rockey 2001). In the field of gastroenterology and hepatology, next to its use in the treatment of esophageal varices and bleeding gastroduodenal ulcers (Guglielmi et al 2002), use in hepatological indications such as portal vein embolization (Kaneko et al 2002), venous malformations or hydatid cysts have been reported (Ormeci et al 2001).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatotoxic effects of polidocanol in a model of autologously perfused porcine livers

et al. 2004

View full text Add to dashboard Cite

Polidocanol is an effective sclerosing agent that consists of 95% hydroxypolyethoxydodecane and 5% ethyl alcohol and is known to have a low risk of complications. However, since the compound has been proposed for the local treatment of liver diseases, the potential for topical hepatic side effects should be examined. Therefore, the new model of normothermic-hemoperfused isolated porcine slaughterhouse livers was used to examine polidocanol-hepatotoxicity encompassing the advantages of slaughterhouse organs to reduce animal experiments and autologous blood as an optimal perfusate. Polidocanol was administered via the hepatic artery and portal vein and the effects of the sclerosant on organ function parameters were compared with those in an untreated control group. In contrast to the untreated control organs, significant differences were found in the polidocanol group for parameters such as alanine aminotransferase or organ weight after perfusion. The most striking differences were found for hepatic bile flow, which dropped in the polidocanol group to 0.24+/-0.02 ml/min per 1000 g after administration of the compound compared with 3.80+/-1.08 ml/min per 1000 g in the control group. In summary, the present observations indicate a risk of hepatotoxic effects of polidocanol. Clinicians should be aware of this problem and the use of polidocanol for intrahepatic sclerosing should be restricted to specialized centers.

show abstract

Section: Mean Sd Mean Sdmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatotoxic effects of polidocanol in a model of autologously perfused porcine livers

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Despite these results and some progress in medical treatment, surgery is still the treatment of choice for uncomplicated hydatid disease of the liver [48,76,103]. Additional alternative methods comprise percutaneous evacuation (PEVAC) and radiofrequency thermal ablation [104,105]. However, only initial experience has been gained in these options.…”

Section: Alternative Proceduresmentioning

confidence: 99%

Echinococcus granulosus infection: the challenge of surgical treatment

Buttenschoen

2003

Langenbeck's Archives of Surgery

119

118

View full text Add to dashboard Cite

Cystectomy and omentoplasty for CE should be the standard surgical procedure because it is safe, simple, and effective and meets all criteria of surgical treatment for hydatid disease: entire elimination of the parasite, no intraoperative spillage especially by using a cone, and saving healthy tissue. Pericystectomy should be used for peripherally located liver cysts that are surrounded by parenchyma only partially. Ultrasonic classification of the parasitic lesion should be used as a guideline for therapeutic measures.

show abstract

“…Pure ethanol (95% concentrate), 20% hypertonic saline, Betadine, silver nitrate, 50% dextrose, 20 % mannitol, 10% albendazole solution are all used for this purpose (12,13). Documented use of 1% polydocanol was first used in this treatment method (14). The significant advantage of 1% polydocanol is the closing of the connection between hydatid cysts and blood vessels or biliary tracts, if there are any.…”

Section: Treatment Of Cementioning

confidence: 99%

PAIR vs Örmeci technique for the treatment of hydatid cyst

Örmeci

2014

Turk J Gastroenterol

View full text Add to dashboard Cite

Hydatid disease is caused by the larval stages of Echinococcus Granulosus. Most patients with hydatid disease have no symptoms, unless there is compression of vital organs such as the hepatic veins, portal vein, hepatic artery in the liver, bronchia in the lungs or the brain, resulting in life threatening complications like anaphylactic shock and sudden death. There are four treatment strategies for cystic echinococcosis (CE)-surgery, percutaneous methods, medical treatments and watch and wait strategies.Medical treatment with albendazol, mebendazole or prazyquentel may cure only 2/3 of patients with CE. More than 30% of patients will reoccur after stopping the treatment. Watch and wait strategy is followed for asymptomatic and small cysts or CE type IV and Type V cysts. Surgical treatments were the gold standard for treatment of CE until the last 30 years. Consequently, surgical methods decreased while percutaneous methods of treatment increased. Due to higher mortality, morbidity, recurrence rates, longer hospital stays and higher costs in comparison to percutaneous methods like PAIR and ÖRMECİ technique, surgical treatment must be limited for the complicated hydatid cyst. Both the PAIR and Örmeci techniques are safe and effective. However, the Örmeci technique offers a simpler, inexpensive method of treatment, with no mortality, lower morbidity, low recurrence rate, while being out patient based. It can be used as the first choice of treatment modality in patients with cysts type CE type one, CE type two, CE Type 3A and CE Type 3B. In this review, treatment modalities for CE, but mainly percutaneous treatment, will be discussed.

show abstract

A new percutaneous approach for the treatment of hydatid cysts of the liver

Cited by 34 publications

References 30 publications

Hepatotoxic effects of polidocanol in a model of autologously perfused porcine livers

Hepatotoxic effects of polidocanol in a model of autologously perfused porcine livers

Echinococcus granulosus infection: the challenge of surgical treatment

PAIR vs Örmeci technique for the treatment of hydatid cyst

Contact Info

Product

Resources

About